RSV

2024 - 6 - 7

How COVID-19 Unleashed RSV: The Pandemic Connection

COVID-19 - FDA Approvals - GSK - Moderna - Monoclonal Antibodies - Respiratory Syncytial Virus (RSV) - Vaccine Research

Discover the surprising link between the COVID-19 pandemic and a rise in RSV cases!

The COVID-19 pandemic brought unexpected consequences beyond the virus itself, affecting other respiratory illnesses like Respiratory Syncytial Virus (RSV). Following the pandemic's onset, changes in RSV diagnostic platforms led to a surge in disease detection rates. This rise in RSV cases caused a significant impact on healthcare systems, with post-pandemic ICU admissions showing a notable increase, particularly for RSV-A cases. The interplay between these two respiratory viruses highlights the complex nature of viral interactions and the ripple effects of global health crises.

Post cover
Image courtesy of "Infectious Disease Advisor"

COVID-19 Pandemic Linked to Changes in RSV Epidemiologic ... (Infectious Disease Advisor)

Changes in RSV diagnostic platforms after the COVID-19 pandemic led to increased disease detection, and post-pandemic ICU admissions were higher for RSV-A ...

RSV research: Nirsevimab 80% effective against hospitalization (CIDRAP)

Two studies highlight new respiratory syncytial virus (RSV) findings, with one estimating that the monoclonal antibody nirsevimab was 80% effective against ...

How COVID-19 Has Impacted RSV Epidemiology Among Children ... (AJMC.com Managed Markets Network)

Respiratory syncytial virus (RSV) hospitalization–related features may help inform prevention approaches among children with the infection, according to one ...

Post cover
Image courtesy of "PrecisionVaccinations"

Monoclonal Antibody Found 75.9% Effective Against RSV-related ... (PrecisionVaccinations)

A Short Communication published by the journal Influenza and Other Respiratory Diseases added to the research-based and real-world evidence the respiratory ...

Post cover
Image courtesy of "Pharmacy Times"

Janssen RSV Protein Vaccine Displays Long-Term Efficacy Among ... (Pharmacy Times)

A single dose of the vaccine showed long-lasting protection against RSV-associated lower respiratory tract disease in older adults.

Post cover
Image courtesy of "STAT"

FDA expands approval for GSK's RSV vaccine to cover younger at ... (STAT)

Following this FDA decision, Arexvy is now the first available RSV vaccine for adults under the age of 60 who are not pregnant.

FDA Approves Expanded Label for GSK RSV Vaccine (Contagionlive.com)

In a move that will make younger adults eligible for RSV vaccines, the FDA approved an expanded label for the GSK RSV vaccine, Arexvy (RSVPreF3 +AS01E), ...

Post cover
Image courtesy of "CBS News"

FDA approves first RSV vaccine for at-risk adults in their 50s (CBS News)

The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk ...

Post cover
Image courtesy of "Chemistry World"

Moderna's mRNA vaccine approved for RSV (Chemistry World)

US approval adds complementary option to protein-based vaccines for respiratory syncytial virus. Moderna's mResvia vaccine has been approved to protect ...

US FDA approves expanded age indication for GSK's Arexvy, the ... (GSK)

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, ...

Post cover
Image courtesy of "CNBC"

FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59 ... (CNBC)

The FDA's expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.

Post cover
Image courtesy of "FiercePharma"

GSK's Arexvy has expanded its label into adults ages 50-59 (FiercePharma)

Thanks to respiratory syncytial virus (RSV) shot Arexvy's new label expansion into a slightly younger pool of adults, GSK is more confident than ever that ...

Post cover
Image courtesy of "Reuters"

US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 (Reuters)

The U.S. Food and Drug Administration approved the expanded use of GSK's respiratory syncytial virus (RSV) vaccine on Friday in adults aged between 50 and ...

Post cover
Image courtesy of "The Straits Times"

US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 (The Straits Times)

RSV vaccines are approved for those above 60; Arexvy is 1st to be approved for this age group. Read more at straitstimes.com.

Explore the last week